The short version of angiotensin IV fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-05-30. Anything still debated is marked as such rather than presented as settled.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
| Property | Value | Notes |
|---|---|---|
| Primary proposed target | HGF/c-Met signaling | Direct binding not confirmed |
| Research models | Rodent and cell studies | Preclinical only |
| Human clinical data | None published | Safety and efficacy unknown |
| Regulatory status | Unapproved research chemical | Status varies by country |
| Typical research purity | 95% or higher by HPLC | Depends on supplier and batch |
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
=== Biological agents === All six of the elements commonly recognised as metalloids have toxic, dietary or medicinal properties. Arsenic and antimony compounds are especially toxic; boron, silicon, and possibly arsenic, are essential trace elements. Boron, silicon, arsenic, and antimony have medical applications, and germanium and tellurium are thought to have potential. Boron is used in insecticides and herbicides. It is an essential trace element. As boric acid, it has antiseptic, antifungal, and antiviral properties. Silicon is present in silatrane, a highly toxic rodenticide. Long-term inhalation of silica dust causes silicosis, a fatal disease of the lungs. Silicon is an essential trace element. Silicone gel can be applied to badly burned patients to reduce scarring. Salts of germanium are potentially harmful to humans and animals if ingested on a prolonged basis. There is interest in the pharmacological actions of germanium compounds but no licensed medicine as yet. Arsenic is notoriously poisonous and may also be an essential element in ultratrace amounts. During World War I, both sides used "arsenic-based sneezing and vomiting agents ... to force enemy soldiers to remove their gas masks before firing mustard or phosgene at them in a second salvo". It has been used as a pharmaceutical agent since antiquity, including for the treatment of syphilis before the development of antibiotics. Arsenic is also a component of melarsoprol, a medicinal drug used in the treatment of human African trypanosomiasis or sleeping sickness.
Reptilian skin is covered in a horny cornified epidermis, making it watertight and enabling reptiles to live on dry land, in contrast to amphibians. Compared to mammalian skin, that of reptiles is rather thin and lacks the thick dermal layer that produces leather in mammals. The scaly skin typical of reptiles was likely inherited from the mutual common ancestor of amniotes, as early synapsids (as well as close relatives of amniotes like diadectomorphs) also had scaly reptile-like skin. This epidermis has differentiated alpha- and beta-keratin layers. Reptile skin varies from being highly pliable (snakes, geckoes) to inflexible (crocodilians, many turtles, many lepidosaurs) and the scales from highly overlapping (skinks and snakes) to having very little overlap (crocodilians, geckoes and agamids). Some areas of the body may not covered in scales (such as large areas of the body in turtles), but still generally have a rough appearance. Large plate-like scales, such as those covering the shells of turtles and the bodies of crocodilians, are referred to as scutes. The tips of reptile digits are generally capped with hard, curved cornified claws.
Marion Walwyn, a cousin who first met Banting in 1901, recalled that "we sat together in the swing in our yard. In an hour he didn't say one word." He continued to struggle in school and stubbornly resisted being disciplined there. After one incident, he resolved never to continue his education but was convinced otherwise by his father. Banting's grandfather, John Banting, had urged his own children to be educated; the philosophy had influenced William, who offered to provide a fund to his sons when they turned twenty-one. In contrast to his brothers, who spent the inheritance towards their own farms, Frederick would use it towards matriculation. In his late teenage years, Banting grew into a tall man with engagements in school football and baseball teams. Both his mother and father hoped that he would find a vocation in the Methodist ministry. He passed physics and chemistry during junior matriculation examinations in 1909, but repeated English and was required to undertake French and Latin. The next year, he narrowly passed Latin but failed French and, for a second time, English composition. The principal later remembered his repeated efforts: "We would not have picked him for one on whom fame should settle. He was a white boy, a right boy."
Jake Melksham (born 29 August 1991) is a former professional Australian rules footballer who played for Melbourne Football Club and the Essendon Football Club in the Australian Football League (AFL). A midfielder, 1.86 metres (6 ft 1 in) tall and weighing 83 kilograms (183 lb), Melksham also has the ability to play as a defender, primarily as a half-back flanker. Growing up in Glenroy, Victoria, he played top-level football early when he joined the Calder Cannons' under 18 side in the TAC Cup at the age of sixteen. He spent three years playing for the Calder Cannons, winning a premiership in his final junior year. His achievements as a junior include state representation and the TAC Medal as the best player on the ground in the TAC Cup Grand Final. Melksham's late surge in his draft year saw him recruited by the Essendon Football Club with the tenth selection in the 2009 AFL draft. He made his AFL debut in the 2010 season and was rewarded with an AFL Rising Star nomination. He spent six seasons with Essendon, which peaked with a fifth-place finish in the best and fairest, and after 114 games with the club, he was traded to the Melbourne Football Club during the 2015 trade period. Before he could play his first match with Melbourne, he was suspended for the 2016 season for his involvement in the Essendon Football Club supplements saga; he was the last remaining player involved in the saga at the time of his retirement in 2026. In November 2023 he was delisted by the Melbourne Football Club, then re-listed in the subsequent rookie draft.
===== Uncoating inhibitors ===== Inhibitors of uncoating have also been investigated. Amantadine and rimantadine have been introduced to combat influenza. These agents act on penetration and uncoating. Pleconaril works against rhinoviruses, which cause the common cold, by blocking a pocket on the surface of the virus that controls the uncoating process. This pocket is similar in most strains of rhinoviruses and enteroviruses, which can cause diarrhea, meningitis, conjunctivitis, and encephalitis. Some scientists are making the case that a vaccine against rhinoviruses, the predominant cause of the common cold, is achievable. Vaccines that combine dozens of varieties of rhinovirus at once are effective in stimulating antiviral antibodies in mice and monkeys, researchers reported in Nature Communications in 2016. Rhinoviruses are the most common cause of the common cold; other viruses such as respiratory syncytial virus, parainfluenza virus and adenoviruses can cause them too. Rhinoviruses also exacerbate asthma attacks. Although rhinoviruses come in many varieties, they do not drift to the same degree that influenza viruses do. A mixture of 50 inactivated rhinovirus types should be able to stimulate neutralizing antibodies against all of them to some degree.
Sources: en.wikipedia.org
Pseudomonas syringae is a rod-shaped, Gram-negative bacterium with polar flagella. As a plant pathogen, it can infect a wide range of species, and exists as over 50 different pathovars, all of which are available to researchers from international culture collections such as the NCPPB, ICMP, and others. Pseudomonas syringae is a member of the genus Pseudomonas, and based on 16S rRNA analysis, it has been placed in the P. syringae group. It is named after the lilac tree (Syringa vulgaris), from which it was first isolated. A phylogenomic analysis of 494 complete genomes from the entire Pseudomonas genus showed that P. syringae does not form a monophyletic species in the strict sense, but a wider evolutionary group that also included other species as well, such as P. avellanae, P. savastanoi, P. amygdali, and P. cerasi. Pseudomonas syringae tests negative for arginine dihydrolase and oxidase activity, and forms the polymer levan on sucrose nutrient agar. Many, but not all, strains secrete the lipopeptide plant toxin syringomycin, and it owes its yellow fluorescent appearance when cultured in vitro on King's B medium to production of the siderophore pyoverdin. Pseudomonas syringae also produces ice nucleation active (INA) proteins which cause water (in plants) to freeze at fairly high temperatures (−1.8 to −3.8 °C (28.8 to 25.2 °F)), resulting in injury. Since the 1970s, P. syringae has been implicated as an atmospheric biological ice nucleator, with airborne bacteria serving as cloud condensation nuclei.
=== Products and endorsements === In November 2018, Collins collaborated with Mark Hill Hair, in which she attended Boots as a beauty brand consultant and dressed in the company uniform to promote their "5 for £50 Pick 'n' Mix" offer on hair curlers for Black Friday. In May 2019, Collins teamed up with Just Eat to appear in an online advert where she tried the new chicken fries from Burger King to promote the latest addition to their menu, that were available on the food delivery service. In April 2020, Collins collaborated with the company Cocoa Plus to release her own range of chocolate bars. She has since released other confectionery including luxury truffles, an advent calendar, and an Easter egg. In July 2020, Collins became the face of low-cost airline Wizz Air. Upon being appointed brand ambassador, Collins said "Anyone who knows me knows I am all about holidays, so Wizz have come to the right person for some travel inspo! Whether it's siestas and fiestas in Marbs or sunbathing and dancing through the night on a Greek Island, I have got a tip or two up my sleeve. Now we can all fly like the GC!". In October, Collins collaborated with Zymurgorium, a distillery in Manchester, to launch her own premium gin liqueur as part of the company's "FlaGINgo" range. In November 2020, Collins partnered with the online casino PlayOJO to launch a faux fragrance, in order to raise awareness that problem gambling is the "addiction with no smell". She admitted that the campaign was close to her heart having previously been around addicts in her life.
==== Agitation of hydrophilic primer or adhesive during application ==== Besides having adequate dentinal moisture, agitation of the primers during application of two-step etch-and-rinse adhesives may be critical for optimal penetration into the demineralized collagen fibres. It also may aid the evaporation of residual water in the adhesive and hybrid layers, thus preventing nano leakage. In a clinical trial comparing the performance of Prime & Bond NT using no rubbing action, slight rubbing action and vigorous rubbing action in the restoration of NCCLs, 92.5% of restorations in vigorous rubbing action group were found to retain after 24 months of clinical service. For the other two groups, the retention rates of the restoration were slightly lower, at 82.5%.
== Awards == German Innovation Award. Excellence in Business to Business – Pharmaceuticals, Winner 2019 German Innovation Award, Fortibone January 2020 Nutra Ingredients Awards. Ingredient of the Year: Healthy Ageing – Fortibone, GELITA – 2018, Winner 2018, January 2020 Life PR Award: German Innovation Award in gold for innovative detergent additive Novotec CB800, June 6, 2018 Nutraceuticals World: Top 100 Innovative Companies in Germany, Category "Innovative Processes" Cannes Corporate Media & TV Awards 2016: Four Dolphins for the company Video "You can see". Gold in category corporate videos and silver in the categories marketing films – B2B, information films and visitors films German Brand Award for successful brand management in the category "Industry Excellence in Branding", 2016 "Intermedia-globe Award" in gold, World Media Festival June 22, 2016 Frost & Sullivan Award, "European Health Ingredient of the Year" – 2008 New Hope, "GELITA Wins Frost & Sullivan Award European Health Ingredient of the Year 2008"
Fluorine-18 (18F, also called radiofluorine) is a fluorine radioisotope which is an important source of positrons. Its half-life is 109.734 minutes, less than two hours, and one of the shortest of radioisotopes with use outside research. It decays by positron emission 96.7% of the time and electron capture 3.3% of the time. Both modes of decay yield stable oxygen-18.
Sources: en.wikipedia.org
Dihexa has been proposed to act through HGF and c-Met signaling. This pathway is linked to synapse formation and cellular growth. Direct binding and the precise molecular step remain uncertain.
No published human clinical trials are available for dihexa. Its safety and effectiveness in people are therefore unknown. Most available evidence comes from animal and cell studies.
Preclinical studies often measure dendritic spine density and synaptic protein levels. Behavioral tests include maze learning and avoidance tasks. These endpoints are indirect and do not establish clinical benefit.
Published human trials are lacking. Most evidence comes from laboratory and animal studies. Therefore, human benefits and risks are not established.